ARC 63012 AR
Alternative Names: FPL 63012 ARLatest Information Update: 18 Jan 2007
At a glance
- Originator AstraZeneca R&D Charnwood
- Class
- Mechanism of Action Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 28 Jan 1999 FPL 63012 AR is now called ARC 63012 AR
- 01 Sep 1995 Astra Charnwood has taken over the development of FPL 63012 AR